[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  LongYield [@LongYield](/creator/twitter/LongYield) on x 4476 followers Created: 2025-07-18 22:04:05 UTC $ABT Abbott Laboratories Earnings Call Key Highlights: (2/2) ⚡ Medical Devices: Electrophysiology (EP) EP delivered another quarter of double-digit growth, supported by ongoing U.S. strength and early international rollout of Volt PFA catheter. Volt’s design enables real-time contact visualization and reduced procedure times, positioning it competitively against existing balloon-based systems. Initial market introduction is focused and selective, leveraging trial site familiarity to drive feedback and procedural confidence. Broader launch and scaling anticipated, with Volt expected to bolster EP segment’s trajectory following sustained historical outperformance. 💓 Cardiac Rhythm Management (CRM) and Heart Failure CRM grew 10%, driven by strong uptake of AVEIR leadless pacemakers in both single and dual-chamber indications. Leadless pacemaker adoption continues rising, with trained physician base expanding XX% YoY and daily implants doubling. AVEIR battery life enhancements and next-gen development in conduction system pacing targeted for pivotal trial launch in 2026. Heart Failure sales rose 14%, led by balanced strength across ventricular assist devices (VADs) and CardioMEMS monitoring system. 🫀 Structural Heart Segment Trends Structural Heart grew 12%, with strong TAVR share gains, TriClip adoption, and MitraClip/Amulet contributions. FDA approval of Tendyne mitral valve replacement and promising developments in transfemoral mitral valve pipeline reinforce portfolio depth. Company actively investing in next-gen Amulet device and pursuing clinical trials to expand indications in LAA closure. Structural Heart TAM expected to expand meaningfully following trial results across the sector, supporting growth acceleration beyond 2025. 🩸 TAVR and Vascular Interventions TAVR sales doubled over two years, driven by international momentum and positive feedback on Navitor valve system. U.S. penetration still nascent (~20% of centers), with sales force doubling YoY to support site expansion and productivity gains. Competitive landscape in Europe further favorable following competitor exit, aligning with upcoming Navitor label expansion into lower-risk categories. Investment in balloon-expandable TAVR technology positions Abbott for sustained presence through the end of the decade. 🧠 Neuromodulation and Vascular Performance Neuromodulation sales up 4%, supported by Eterna rechargeable SCS system adoption in international markets. Vascular sales rose 3.5%, driven by strong growth in imaging, vessel closure, and new contributions from Esprit resorbable stent. Portfolio reflects diversified procedural offerings with innovation in chronic and acute vascular solutions supporting long-term growth. 💰 Margins, Currency & Tariff Impact FX had a favorable XXX% impact on Q2 sales, but remains a headwind to EPS YoY; projected to be neutral for full-year sales. Tariff headwinds now expected to impact EPS by ~$200 million, modestly lower than earlier guidance, with mitigation strategies underway. Full-year adjusted EPS midpoint maintained despite lower revenue guidance, reflecting strong operational leverage and expense control. Abbott remains confident in long-term outlook, maintaining targets of high single-digit sales growth, margin expansion, and double-digit EPS. XXX engagements  **Related Topics** [realtime](/topic/realtime) [quarterly earnings](/topic/quarterly-earnings) [$abt](/topic/$abt) [abbott laboratories](/topic/abbott-laboratories) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/LongYield/status/1946330157951651917)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
LongYield @LongYield on x 4476 followers
Created: 2025-07-18 22:04:05 UTC
$ABT Abbott Laboratories Earnings Call Key Highlights: (2/2)
⚡ Medical Devices: Electrophysiology (EP)
EP delivered another quarter of double-digit growth, supported by ongoing U.S. strength and early international rollout of Volt PFA catheter.
Volt’s design enables real-time contact visualization and reduced procedure times, positioning it competitively against existing balloon-based systems.
Initial market introduction is focused and selective, leveraging trial site familiarity to drive feedback and procedural confidence.
Broader launch and scaling anticipated, with Volt expected to bolster EP segment’s trajectory following sustained historical outperformance.
💓 Cardiac Rhythm Management (CRM) and Heart Failure
CRM grew 10%, driven by strong uptake of AVEIR leadless pacemakers in both single and dual-chamber indications.
Leadless pacemaker adoption continues rising, with trained physician base expanding XX% YoY and daily implants doubling.
AVEIR battery life enhancements and next-gen development in conduction system pacing targeted for pivotal trial launch in 2026.
Heart Failure sales rose 14%, led by balanced strength across ventricular assist devices (VADs) and CardioMEMS monitoring system.
🫀 Structural Heart Segment Trends
Structural Heart grew 12%, with strong TAVR share gains, TriClip adoption, and MitraClip/Amulet contributions.
FDA approval of Tendyne mitral valve replacement and promising developments in transfemoral mitral valve pipeline reinforce portfolio depth.
Company actively investing in next-gen Amulet device and pursuing clinical trials to expand indications in LAA closure.
Structural Heart TAM expected to expand meaningfully following trial results across the sector, supporting growth acceleration beyond 2025.
🩸 TAVR and Vascular Interventions
TAVR sales doubled over two years, driven by international momentum and positive feedback on Navitor valve system.
U.S. penetration still nascent (~20% of centers), with sales force doubling YoY to support site expansion and productivity gains.
Competitive landscape in Europe further favorable following competitor exit, aligning with upcoming Navitor label expansion into lower-risk categories.
Investment in balloon-expandable TAVR technology positions Abbott for sustained presence through the end of the decade.
🧠 Neuromodulation and Vascular Performance
Neuromodulation sales up 4%, supported by Eterna rechargeable SCS system adoption in international markets.
Vascular sales rose 3.5%, driven by strong growth in imaging, vessel closure, and new contributions from Esprit resorbable stent.
Portfolio reflects diversified procedural offerings with innovation in chronic and acute vascular solutions supporting long-term growth.
💰 Margins, Currency & Tariff Impact
FX had a favorable XXX% impact on Q2 sales, but remains a headwind to EPS YoY; projected to be neutral for full-year sales.
Tariff headwinds now expected to impact EPS by ~$200 million, modestly lower than earlier guidance, with mitigation strategies underway.
Full-year adjusted EPS midpoint maintained despite lower revenue guidance, reflecting strong operational leverage and expense control.
Abbott remains confident in long-term outlook, maintaining targets of high single-digit sales growth, margin expansion, and double-digit EPS.
XXX engagements
Related Topics realtime quarterly earnings $abt abbott laboratories stocks healthcare